



Solenio Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

January 4, 2021

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company's website at www.solenio.life.

About Solenio Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.solenio.life.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Solenio Therapeutics